NeuroScientific Biopharmaceuticals has reported significant outcomes from its Special Access Program treating fistulising Crohn’s disease with the company's StemSmart mesenchymal stem cell therapy.

Vitrafy Managing Director and CEO Brent Owens added, "The final Phase II report from USAISR delivers independent validation that our decentralised, no-wash platelet preservation platform exceeds regulatory and quality guidelines on every meaningful measure."

Avecho Biotechnology has announced that it has completed the treatment phase for the final patient needed for the planned interim analysis of its pivotal Phase 3 insomnia trial.

Australian innovators are addressing pressing health challenges worldwide and securing pharmaceutical patents at levels comparable to those of Israel and Switzerland.

The material will be presented by CSL at the Options for the Control of Influenza XIII Conference in August in Washington, DC, and will relate to how Noxopharm’s novel oligonucleotides from its Sofra technology platform could be used to improve the delivery of self-amplifying mRNA vaccines.

Nyrada has reported that its lead drug candidate Xolatryp demonstrated clear anti-tumour activity in a rodent model of liver cancer, both alone and in combination with the anthracycline chemotherapy doxorubicin.

OncoSil Medical has secured approval from the Australian Therapeutic Goods Administration for its OncoSil device to be used alongside gemcitabine-based chemotherapy for patients with unresectable locally advanced pancreatic cancer.

Patrys has taken a step toward clinical-stage development of its RLS-2202 program by appointing CMAX as the Phase 1A clinical trial site and Alithia Life Sciences as the contract research organisation to manage the study.

Cleo Diagnostics has outlined the first stage of its United States commercialisation and reimbursement plan for its Pre‑Surgical Ovarian Cancer Test as it moves toward anticipated FDA clearance.

Leaders from Australia’s medical technology sector have gathered in Perth for AusMedtech 2026 to explore innovation, translation and commercialisation across the medtech ecosystem.

AusBiotech Invest Perth 2026 will open its doors in Perth today, bringing together investors, life sciences companies, and global partners focused on the next generation of breakthroughs.

AVITA Medical has reported a cautious but positive start to 2026, with first-quarter revenue of approximately $19.3 million, up 4 per cent year over year and roughly 10 per cent sequentially, driven by contributions from Cohealyx and improving RECELL utilisation.

OncoSil Medical presented interim results from the OSPREY Registry at ESGE Days 2026, reporting encouraging real-world safety and efficacy outcomes for patients with unresectable locally advanced pancreatic cancer treated with EUS-guided phosphorus-32 microparticles.

Racura Oncology has received clearance from its Safety Review Committee to escalate the RC220 dose in the Phase 1 CPACS trial following a review of safety and pharmacokinetic data from the first cohort.

AusBiotech says the 2026-27 Federal Budget sends strong signals that the Government has listened to its advocacy, but the peak life sciences body is urging careful scrutiny of the tax changes to understand their true impact.

AusBiotech has launched the latest edition of the Australasian Biotechnology Journal ahead of AusMedtech 2026, bringing together perspectives from across Australia’s life sciences ecosystem.

The study is part of Neurizon’s broader NUZ-001 program and runs alongside the company’s participation in the Phase 2/3 HEALEY ALS Platform Trial in the United States.